Healthcare -
Biotechnology - NASDAQ - US
$ 5.65
1.62 %
$ 49.2 M
Market Cap
-2.6
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
CervoMed Inc.
| Current Assets | 43.1 M |
| Cash & Short-Term Investments | 38.9 M |
| Receivables | 2.25 M |
| Other Current Assets | 1.91 M |
| Non-Current Assets | 0 |
| Long-Term Investments | 0 |
| PP&E | 0 |
| Other Non-Current Assets | 0 |
| Current Liabilities | 3.88 M |
| Accounts Payable | 1.51 M |
| Short-Term Debt | 0 |
| Other Current Liabilities | 2.37 M |
| Non-Current Liabilities | 2.37 M |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 2.37 M |
EFFICIENCY
Earnings Waterfall
CervoMed Inc.
| Revenue | 9.74 M |
| Cost Of Revenue | 18.8 M |
| Gross Profit | -9.06 M |
| Operating Expenses | 28 M |
| Operating Income | -18.2 M |
| Other Expenses | -1.94 M |
| Net Income | -16.3 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
CervoMed Inc.
| Net Income | -16.3 M |
| Depreciation & Amortization | 0 |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 1.41 M |
| Change in Working Capital | -441 K |
| Others | -2.49 M |
| Free Cash Flow | -16.5 M |
Wall Street Analysts Price Targets
CervoMed Inc.
Wall Street analysts predict an average 1-year price target for CRVO of $57 , with forecasts ranging from
a
low of
$55 to a high of $65 .
CRVO Lowest Price Target
Wall Street Target
55 USD
873.45%
CRVO Average Price Target
Wall Street Target
57 USD
908.85%
CRVO Highest Price Target
Wall Street Target
65 USD
1050.44%
4. DIVIDEND
ANALYSIS
CRVO does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
CervoMed Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
35.8 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
18.2 K USD 1
9-12 MONTHS
7. News
CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates
CervoMed Inc. (CRVO) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.41 per share a year ago.
zacks.com
- 1 month ago
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB)
globenewswire.com
- 1 month ago
Biotech Stocks Q1 2025 Recap: Winners And Underperformers
Investing in biotech can be highly rewarding but is fraught with risks; understanding past catalysts can help investors make informed decisions and minimize downside risk. CervoMed Inc. surged over 300% in Q1 2025 due to positive Phase 2b trial results for its lead drug candidate, neflamapimod despite earlier setbacks. Chimerix Inc. gained over 144% after announcing an acquisition by Jazz Pharmaceuticals and positive FDA feedback on its lead drug candidate, dordaviprone.
seekingalpha.com
- 3 months ago
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver an oral presentation at the 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™), being held on April 1-5, 2025 in in Vienna, Austria. The Company will be presenting detailed analyses from the Extension Phase of the RewinD-LB Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB).
globenewswire.com
- 3 months ago
CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats
CervoMed's stock surged more than 400% after interim data showed significant improvement with a new batch of neflamapimod in treating Dementia with Lewy Bodies. The recent interim readout deserves excitement, but I do express several concerns related to, among others, potential learning and placebo effects, subjective CDR-SB results, and lack of biomarker data. CervoMed is well-funded into 2026, but may need additional funds for further trials to bring neflamapimod to market for DLB.
seekingalpha.com
- 3 months ago
CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies
A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p
globenewswire.com
- 3 months ago
CervoMed to Present at the 8th International Lewy Body Dementia Conference
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that topline results from the Phase 2b RewinD-LB study will be presented at the 8th International Lewy Body Dementia Conference (ILBDC), being held in Amsterdam, on January 31, 2025. The initial topline results for the Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB) were previously disclosed on December 10, 2024 and are available here.
globenewswire.com
- 5 months ago
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (the “Company”), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that it has granted equity awards as a material inducement to the employment of two new employees.
globenewswire.com
- 6 months ago
CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets
On Tuesday, CervoMed Inc. CRVO stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for dementia with Lewy bodies (DLB).
benzinga.com
- 6 months ago
CervoMed's stock craters 77% after failed trial of treatment for rare brain disease
CervoMed Inc.'s stock cratered early Tuesday after the biotech company said a midstage trial of a treatment for patients with dementia with Lewy bodies, or DLB, failed to meet its main goals.
marketwatch.com
- 6 months ago
CervoMed's dementia drug fails to meet mid-stage trial goals
U.S. drug developer CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary goals in a mid-stage clinical trial.
reuters.com
- 6 months ago
CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
—Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks—
globenewswire.com
- 6 months ago
8. Profile
Summary
CervoMed Inc. CRVO
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 49.2 M
Dividend Yield
0.00%
Description
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
Contact
20 Park Plaza, Boston, MA, 02116
https://www.cervomed.com
IPO
Date
May 23, 2008
Employees
15
Officers
Dr. Robert J. Cobuzzi Jr., Ph.D.
Chief Operating Officer & Director
Dr. John J. Alam M.D.
Co-Founder, Chief Executive Officer, President & Director
Dr. Mark A. De Rosch Ph.D.
Executive Vice President of Regulatory, Government Affairs & Program Management
Ms. Kelly Blackburn M.H.A.
Executive Vice President of Clinical Development
Dr. Sylvie L. Gregoire Pharm.D.
Co-Founder & Director
Mr. William Robert Elder J.D.
Chief Financial Officer, General Counsel & Corporate Secretary
Dr. Claudia Ordonez M.D.
Senior Vice President of Medical Science